Malenti Strings: Intrapreneurship within FLG, Inc. Case Solution
The case informs the story of Synthroid from its advancement in 1958 as the very first artificial thyroxine particle to its competitors versus general substitutes in 2004. Since Synthroid was established and presented prior to FDA guidelines and drug requirements of identity were totally developed, it was tough for rivals to get their drugs accredited as similar to Synthroid. Through a series of attempts with doctors, specifically endocrinologists, Synthroid’s owners were capable to keep the understanding for forty-six years that Synthroid was distinctively reliable.
Trainees are challenged to think about alternatives to keep the drug’s system volume, profits, and/or earnings in these challenging situations. The (A) case offers overview on the history of the drug, the pharmaceutical market and its advertising process, and hypothyroidism and its procedure, and it concludes in 2004 as Abbott’s online marketers deal with the approaching obstacle of safeguarding the Synthroid organisation versus generic competitors.
This case is about REORGANIZATION
PUBLICATION DATE: October 11, 2016
Related Case Solutions:
Malenti Strings: Intrapreneurship within FLG, Inc.
The Case of Synthroid (A), Spanish Version
The Case of Synthroid (B)
The Case of Synthroid (A)
Alcatel’s Merger with Lucent, 2006
Alcatel S.A. and Lucent Technologies: The Effect of Acquisitions on Net Operating Losses
The Case of Synthroid (B)
China: To Float or Not to Float? (F): Alcatel and Strong Chinese Competition
China: To Float or Not to Float (F): Alcatel and Strong Chinese Competition
Intrapreneurship at Alcatel-Lucent